The IVDR transition deadline is approaching

Incomplete Technical Documentation submissions are one of the most common reasons for delays to the certification process.
To make the process more efficient for you, access the key resources you need to help you prepare.

New Active Implantable Devices brochure 

As one of the highest risk categories of device, Active Implantable Medical Devices (AIMDs) are subject to rigorous regulatory controls before they can reach global markets. It is critical to work with a notified body that
understands the industry and has the experience to review and confirm your products’ readiness for market – efficiently, reliably and promptly.

Talk to us today about your CE Marking requirements.

Find out more

Download the AIMD brochure

Hear Dr Jayanth Katta talk at the MedTech Digital Week

BSI kicked off the MedTech Digital Week run by Informa. Dr Jayanth Katta, Senior Regulatory Lead (Medical Devices) presented on EU Medical Device Regulations, Notified Body Overview and Update from BSI on initial lessons learned from MDR audits.

Listen back to Jay’s session

BSI’s perspectives on Article 117 and drug-device combinations

Introduced by the European Commission under the Medical Devices Regulation (MDR), Article 117 requires manufacturers placing drug-device combination products onto the market as an integral device and marketing them as a “medicinal product” to seek a Notified Body Opinion (NBOp).

Listen back to our Webinar to hear Dr Jennifer Durrant, Global Head of Medicinal and Biologics and Dr Jonathan Sutch, Medicinal Technical Specialist about BSI’s perspective on Article 117 and drug-device combination products.

Listen back to the on demand webinar

More about Article 117

New BSI medical devices white paper: Medical device clinical investigations – what’s new under the MDR?

The conduct of a clinical investigation is one of the most time consuming and resource intensive activities that a medical device manufacturer can face. This paper discusses important new requirements for pre-market and post-market clinical investigations under the European MDR. It also addresses the importance of defining the regulatory purpose of a study, the relationship of
a clinical investigation with quality management system (QMS) practices and strategies for conducting a successful clinical investigation, including the importance of defining the steps for its planning and conduct.

Download white paper 

인사팀

카카오톡에서 BSI Korea 친구추가 하시고,
최신 표준 소식교육 할인 정보를 무료로 받아보세요!





BSI 블로그에 개재된 모든 글의 무단 복사 및 재배포를 금지합니다.
반드시 출처를 남겨주세요.


  • 1901년에 설립되어 현재 120년의 역사를 보유한, 세계 최초의 국가표준 제정기구
  • ISO(국제표준화기구)의 창립 멤버로서, ISO 이사회 및 CEN(유럽표준화위원회) 이사회의 영구 이사 자격 보유
  • ISO 9001(품질경영시스템), ISO 14001(환경경영시스템), ISO 27001(정보보호경영시스템) 등 주요 국제표준의 근간 문서를 다수 발행
  • 영국의 왕실 인정 기구(Royal Charter)이자, 영국 국가표준 제정기구(NSB)
  • 표준에 대한 가장 경험이 풍부한 기관으로서, 전세계 193개국 86,000여 고객과 협업
  • 미국 및 영국 시장점유율 1위에 해당하는 국제표준 인증기관으로서, 조직의 리스크관리, 성과개선, 비용절감, 지속가능성 보장을 지원하기 위한 표준 개발, 인증, 심사, 교육 전문 기관
  • 전세계 70여 BSI 사무소 보유로 글로벌 사업장 동시 대응 가능 및 브렉시트에 따른 시장 변화를 즉각 지원 가능한 거의 유일한 기관